Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

Biomea Fusion reported Q1 2026 net loss of $12.4 million, down significantly from $29.3 million in Q1 2025, driven by reduced R&D and G&A expenses following headcount reductions. The company announced positive 52-week data from its Phase II COVALENT-112 trial showing icovamenib achieved a 52% increase in C-peptide levels in recently diagnosed type 1 diabetes patients with durability through Week 52. Two Phase II type 2 diabetes trials (COVALENT-211 and COVALENT-212) are enrolling with topline data expected in Q4 2026, while the Phase I obesity trial (GLP-131) is on track with initial weight reduction data expected in Q2 2026. Cash runway is projected into Q1 2027.

05/11/2026, 4:54 PM • GlobeNewswire

Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions

Biomea Fusion announced that three abstracts on icovamenib, its investigational oral menin inhibitor, have been selected for late-breaking poster presentations at the ADA 86th Scientific Sessions in June 2026. The presentations will showcase data from Phase 2 trials (COVALENT-111 and COVALENT-112) demonstrating icovamenib's potential to improve beta cell function and insulin secretion in both type 1 and type 2 diabetes patients, including those on background GLP-1 therapy.

05/05/2026, 5:50 PM • GlobeNewswire

Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies

Biomea Fusion announced the first patient dosing in two Phase II clinical trials (COVALENT-211 and COVALENT-212) evaluating icovamenib for type 2 diabetes patients failing standard-of-care therapies. COVALENT-211 targets insulin-deficient T2D patients, while COVALENT-212 targets patients uncontrolled on GLP-1 receptor agonists. Both studies will enroll approximately 60 patients each, with topline 26-week primary endpoint data anticipated in Q4 2026. The trials build on positive Phase II COVALENT-111 data showing durable HbA1c reductions of up to 1.8% that persisted nine months post-treatment.

03/31/2026, 7:00 AM • GlobeNewswire

Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026

Biomea Fusion announced positive 52-week follow-up results from its Phase II COVALENT-111 study of icovamenib in type 2 diabetes patients. The drug demonstrated durable efficacy nine months post-dosing, with severe insulin-deficient diabetes patients achieving a 1.2% HbA1c reduction at Week 52. The company maintained a favorable safety profile and plans to advance two new Phase II studies targeting specific patient populations.

03/14/2026, 4:30 AM • GlobeNewswire

Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025

Dr. Ralph DeFronzo presented insights on icovamenib, a potential disease-modifying therapy for diabetes, highlighting its ability to restore beta cell mass and function through menin inhibition during the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease.

12/09/2025, 6:35 PM • GlobeNewswire

Biomea Fusion to Present Poster Presentations at ObesityWeek®2025

Biomea Fusion will present two poster presentations at ObesityWeek® 2025, highlighting preclinical data for BMF-650, an oral GLP-1 receptor agonist, and combination data for icovamenib with semaglutide.

10/30/2025, 8:00 AM • GlobeNewswire

Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series

Biomea Fusion, a clinical-stage diabetes and obesity company, will participate in Citi's SMID Biotech C-Suite Fireside Chat Series on October 23, 2025, offering a live audio webcast of the discussion.

10/21/2025, 7:05 PM • GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Biomea Fusion granted a new employee non-qualified stock options to purchase 48,000 shares of common stock, with shares vesting quarterly over four years under the company's 2023 Inducement Equity Plan.

10/01/2025, 7:00 AM • GlobeNewswire

Biomea Fusion (BMEA) Q2 Loss Drops 44%

Biomea Fusion reported a reduced net loss of $20.7 million in Q2 2025, down from $37.3 million in the same period of 2024. The biotechnology company focused on metabolic disease treatments showed progress in cost management and clinical development of its lead drug icovamenib for diabetes and potential obesity treatments.

08/05/2025, 10:21 PM • The Motley Fool

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Biomea Fusion presented new data on its investigational diabetes drug icovamenib at the ADA conference, highlighting its potential to enhance glycemic control and promote weight loss when combined with GLP-1 therapies, while preserving lean mass.

06/23/2025, 7:00 AM • GlobeNewswire